Clinical outcomes of resected EGFR positive stage I-III NSCLC patients in the Midlands, UK

被引：0
|
作者：
Powell, R. L. [1 ]
Murukesh, N. [2 ]
Seeva, P. [2 ]
Solanki, A. [3 ]
Singh, A. [3 ]
Jain, A. [4 ]
Elmasry, A. R. [5 ]
Jegannathen, A. [5 ]
Irwin, A. [6 ]
Ghafoor, Q. [6 ]
O'Sullivan, B. [6 ]
Taniere, P. [7 ]
Baijal, S. [8 ]
机构：
[1] Univ Hosp Birmingham NHS Fdn Trust, Clin Haematol & Oncol Dept, Heartlands Hosp, Birmingham, W Midlands, England
[2] Worcestershire Royal Hosp, Dept Oncol, Worcester, England
[3] Royal Wolverhampton NHS Trust, New Cross Hosp, Deanesly Ctr, Wolverhampton, England
[4] New Cross Hosp, Royal Wolverhampton Hosp NHS Trust, Wolverhampton, England
[5] Univ Hosp North Midlands, Stoke On Trent, Staffs, England
[6] New Queen Elizabeth Hosp Birmingham, Oncol, Birmingham, W Midlands, England
[7] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England
[8] Heart England NHS Fdn Trust, Heartlands Hosp, Birmingham, W Midlands, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
67P
引用
收藏
页码：S731 / S732
页数：2
相关论文
共 50 条
  • [41] Clinical characteristics and real-world treatment patterns in stage I-III resectable NSCLC: THASSOS-INTL study
    Prabhash, K.
    Moor, R.
    Goksel, T.
    Nyaw, S. F.
    Altwairgi, A. K.
    Hernandez, F. J. Gonzalez
    Mohamed, E.
    Kantharaju, P.
    Sadek, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S790 - S790
  • [42] Clinico-pathological data and prognostic factors in completely resected AJCC stage I-III liposarcomas
    Nijhuis, PHA
    Sars, PRA
    Plaat, BEC
    Molenaar, WM
    Sluiter, WJ
    Hoekstra, HJ
    ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (07) : 535 - 543
  • [43] Surgical treatment experience for patients with stage I-III esophageal cancer
    Kolesnik, O. P.
    Kolesnyk, I. P.
    Kechedzhyiev, V. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2018, (03) : 448 - 453
  • [44] The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I-III resected NSCLC without known EGFR mutations.
    Gray, Jhanelle Elaine
    Salomonsen, Rachel
    Georgoulia, Nefeli
    Perez, Ignacio Diaz
    Wang, Alice
    Cai, Ling
    Wetherill, Graham
    Xiao, Yang
    Fielden, Claire
    Altorki, Nasser K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] CTL ANTIGEN 4 (CTLA-4) AND KI67 AS PROGNOSTIC FACTORS IN RESECTED STAGE I-III NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Rijavec, E.
    Dal Bello, M. G.
    Sini, C.
    Genova, C.
    Barletta, G.
    Laurent, S.
    Truini, M.
    Pistillo, M. P.
    Merlo, D.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S35 - S35
  • [46] Ribonucleotide reductase subunit 2 (RRM2) to predict shorter survival in resected stage I-III non-small cell lung cancer (NSCLC) patients.
    Rijavec, Erika
    Dal Bello, Maria Giovanna
    Savarino, Graziana
    Sini, Claudio
    Barletta, Giulia
    Genova, Carlo
    Truini, Mauro
    Pronzato, Paolo
    Merlo, Domenico Franco
    Pfeffer, Ulrich
    Grossi, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] The Impact of EGFR Mutations on the Prognosis of Patients with Resected Stage I Lung Adenocarcinoma
    Kitamura, Jiro
    Tapias, Luis
    Mathisen, Douglas
    Lanuti, Michael
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S620 - S621
  • [48] Pattern of Postoperative Recurrence and Clinical Value of Adjuvant Radiotherapy in Completely Resected Stage III/N2 EGFR-Mutant NSCLC
    Ni, J.
    Guo, T.
    Li, Y.
    Zhu, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1098 - S1098
  • [49] CD34+ and SMA+ cancer-associated fibroblasts influence prognosis in stage I-III NSCLC patients
    Schulze, A. B.
    Schmidt, L. H.
    Heitkoetter, B.
    Huss, S.
    Mohr, M.
    Marra, A.
    Hillejan, L.
    Goerlich, D.
    Barth, P. J.
    Rehkaemper, J.
    Evers, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 144 - 144
  • [50] Clinical Outcomes of Concurrent Chemoradiation vs RT alone in Elderly Patients with Stage III NSCLC
    Kim, D. Y.
    Kim, J.
    Song, C.
    Lee, J. S.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S397 - S397
12345